Skip to main content
    8

    89bio Inc (ETNB)

    BIOTECHNOLOGY

    $14.84
    +0.00 (+0.00%)

    Last updated: Oct 30, 2025 at 5:00 PM ET

    89bio Inc (ETNB) Financials: Revenue, Profit and Cash Flow

    Updated Aug 7, 2025. Financial statements from company filings, amounts in US dollars.

    89bio reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$367.08M, operating cash flow was -$367.82M and free cash flow was -$367.84M. The quarter ended Jun 30, 2025 had revenue of $0 and net income of -$111.50M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $384.66M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Jun 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenue$0$0$0$0$0$0$6.00K
    Gross profit$0$0$0$0$0$0-$6.00K
    Research and development$345.04M$122.23M$80.80M$70.33M$36.20M$21.35M$13.68M
    Operating income-$384.66M-$151.20M-$102.25M-$89.74M-$49.35M-$26.64M-$15.16M
    Net income-$367.08M-$142.19M-$102.03M-$90.12M-$49.50M-$57.42M-$16.18M
    EBITDA-$370.20M-$138.85M-$100.24M-$88.03M-$49.00MN/AN/A
    Fiscal years ended Dec 2018 to Dec 2024

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Revenue$0$0$21.00K$0$0$0$234.00K$0$0$0$0$0
    Gross profit$0$0$21.00K$0$0$0-$16.00K$0$0$0-$55.00K$0
    Operating income-$115.82M-$75.91M-$122.00M-$151.94M-$53.44M-$57.28M-$41.21M-$39.34M-$42.13M-$28.52M-$25.36M-$27.04M
    Net income-$111.50M-$71.28M-$118.35M-$149.07M-$47.97M-$51.68M-$40.23M-$34.73M-$38.39M-$28.84M-$24.60M-$26.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded long-term debt of $35.73M by $90.33M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$478.69M$596.27M$196.82M$162.42M$211.07M$95.55M$11.37M
    Current assets$476.45M$593.53M$196.08M$161.98M$210.20M$95.33M$11.32M
    Cash and equivalents$126.06M$316.16M$55.26M$52.43M$98.18M$93.33M$11.23M
    Total liabilities$77.90M$59.96M$44.99M$36.47M$8.11M$5.61M$4.35M
    Short-term debtN/AN/AN/A$2.50M$0N/AN/A
    Long-term debt$35.73M$24.80M$20.19M$16.90M$0N/AN/A
    Shareholder equity$400.79M$536.31M$151.83M$125.96M$202.96M$89.94M-$16.06M
    Fiscal years ended Dec 2018 to Dec 2024

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total assets$603.49M$685.03M$478.69M$458.30M$582.14M$577.32M$596.27M$460.11M$492.51M$494.32M$196.82M$200.58M
    Total liabilities$81.75M$79.57M$77.90M$80.19M$67.22M$66.78M$59.96M$49.90M$50.52M$48.49M$44.99M$48.01M
    Cash and equivalents$129.08M$315.40M$126.06M$91.41M$212.22M$217.57M$316.16M$251.93M$245.44M$350.93M$55.26M$72.40M
    Shareholder equity$521.73M$605.46M$400.79M$378.10M$514.92M$510.54M$536.31M$410.21M$441.99M$445.83M$151.83M$152.57M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$367.82M-$129.19M-$81.09M-$76.78M-$46.24M-$25.46M-$12.47M
    Capital expenditures$15.00K$4.00K$7.00K$63.00K$126.00K$139.00K$39.00K
    Free cash flow-$367.84M-$129.19M-$81.10M-$76.84M-$46.37M-$25.60M-$12.51M
    Dividends paidN/A$268.00KN/A$19.95MN/AN/AN/A
    Share repurchases$253.00K$0$0N/AN/AN/AN/A
    Investing cash flow-$40.86M-$123.02M-$33.94M$7.16M-$106.83M-$139.00K-$39.00K
    Financing cash flow$218.59M$513.11M$117.83M$23.87M$157.92M$107.70M$23.77M
    Fiscal years ended Dec 2018 to Dec 2024

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$100.42M-$71.74M-$121.58M-$145.36M-$61.16M-$39.72M-$34.29M-$30.36M-$34.45M-$30.09M-$27.10M
    Capital expenditures$0$72.00K$15.00K$0$0$0$4.00K$0$0$0$2.00K
    Free cash flow-$100.42M-$71.81M-$121.59M-$145.36M-$61.16M-$39.72M-$34.30M-$30.36M-$34.45M-$30.09M-$27.10M
    Last 11 quarters

    Frequently Asked Questions About ETNB

    What is 89bio's annual revenue?

    89bio reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is 89bio profitable?

    No. 89bio reported net income of -$367.08M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does ETNB generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$367.82M minus capital expenditures of $15.00K produced free cash flow of -$367.84M.

    How much debt does 89bio have?

    The balance sheet dated Dec 31, 2024 reported long-term debt of $35.73M and cash and equivalents of $126.06M.